Jean-Baptiste Julla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Baptiste Julla has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Pierre Riveline
Department of Endocrinology and Diabetology, Lariboisière Hospital, APHP, Paris-Cité University Paris, Paris, France
4 shared publications - Nicolas Venteclef
INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France
4 shared publications - Jean-François Gautier
INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France; Centre Universitaire du Diabète et de ses Complications, AP-HP, Hôpital Lariboisière, INSERM UMR-S1151, CNRS UMR-S8253, Immediab Lab, Institut Necker-Enfants Malades, Université Paris Cité, Paris, France
3 shared publications Louis Potier
INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France; AP-HP, Bichat-Claude-Bernard Hospital, Diabetology, Endocrinology Department, Paris, France
3 shared publications- Pierre-Jean Saulnier
University of Poitiers, INSERM, CHU Poitiers, clinical investigation center CIC 1402, Poitiers, France
3 shared publications Agnès Sola Gazagnes
Department of Diabetology, Assistance Publique—Hôpitaux de Paris, Cochin Hospital Diabetology and Clinical Immunology Service, Paris, France
2 shared publications
Latest Publications
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- 10 July 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Sustained Follow-up of Automated Insulin Delivery in a Real-World Setting: Results at 2 Years of the French Nationwide Observatory OB2F
Background: Automated insulin delivery (AID) systems improve glycemic control in people with type 1 diabetes (PwT1D), but evidence on effectiveness and safety in routine clinical practice over 2 years remains limited. Methods: The Observatoire de la Boucle Fermée en France is a nationwide prospective observational study evaluating AID use in children and adults with type 1 diabetes in real-world conditions. The primary end point was time in range (TIR, 70–180 mg/dL). The primary analysis assessed the noninferiority of TIR at 24 months (M24) compared with 12 months (M12). Secondary analyses evaluated the superiority of glycemic outcomes at M24 versus baseline (M0), including HbA1c, continuous glucose monitoring metrics, and safety outcomes. A sensitivity analysis using a linear mixed-effects model examined the change in TIR between M0 and M24 according to baseline HbA1c (P < 0.0001), and HbA1c decreased from 7.6% to 7.1% ( P < 0.0001). AID discontinuation at M24 occurred in 2.1% of participants. The proportions of participants experiencing at least one episode of severe hypoglycemia over the preceding 12 months were lower at M24 than at baseline. A significant interaction between time of AID use and baseline HbA1c category was observed ( P < 0.001). At M24, TIR remained higher in participants with baseline HbA1c P < 0.0001). Conclusions: In a large nationwide real-world cohort, AID use was associated with noninferior TIR between 12 and 24 months, significant improvements in glycemic outcomes compared with baseline, low rates of treatment discontinuation, and favorable safety outcomes.
- 10 July 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Sustained Follow-up of Automated Insulin Delivery in a Real-World Setting: Results at 2 Years of the French Nationwide Observatory OB2F
Background: Automated insulin delivery (AID) systems improve glycemic control in people with type 1 diabetes (PwT1D), but evidence on effectiveness and safety in routine clinical practice over 2 years remains limited. Methods: The Observatoire de la Boucle Fermée en France is a nationwide prospective observational study evaluating AID use in children and adults with type 1 diabetes in real-world conditions. The primary end point was time in range (TIR, 70–180 mg/dL). The primary analysis assessed the noninferiority of TIR at 24 months (M24) compared with 12 months (M12). Secondary analyses evaluated the superiority of glycemic outcomes at M24 versus baseline (M0), including HbA1c, continuous glucose monitoring metrics, and safety outcomes. A sensitivity analysis using a linear mixed-effects model examined the change in TIR between M0 and M24 according to baseline HbA1c (P < 0.0001), and HbA1c decreased from 7.6% to 7.1% ( P < 0.0001). AID discontinuation at M24 occurred in 2.1% of participants. The proportions of participants experiencing at least one episode of severe hypoglycemia over the preceding 12 months were lower at M24 than at baseline. A significant interaction between time of AID use and baseline HbA1c category was observed ( P < 0.001). At M24, TIR remained higher in participants with baseline HbA1c P < 0.0001). Conclusions: In a large nationwide real-world cohort, AID use was associated with noninferior TIR between 12 and 24 months, significant improvements in glycemic outcomes compared with baseline, low rates of treatment discontinuation, and favorable safety outcomes.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude du rôle des monocytes dans la pathogénèse du diabète et de ses complications
Introduction: Les patients diabétiques de type 2 (DT2) sont à haut risque de complications cardiovasculaires (CV) et de formes graves de COVID19. Le DT2, l’athérosclérose et le COVID-19 ont une pathogenèse liée à un état inflammatoire pathologique. Les monocytes (Mono) sont capables d’avoir une action propre anti- ou pro-inflammatoire, mais aussi de s’infiltrer dans les tissus et de s’y différencier en macrophages. Nous testons l’hypothèse qu’ils pourraient être associés à la mise en place du diabète et de ces 2 complications. Méthodes : Les Mono (totaux et sous-types) d’une cohorte de DT2 ont été quantifiés (en immunophénotypage(IP)), leurs corrélations avec les données clinicobiologiques et CV ont été étudiées. Le modèle du diabète gestationnel a été utilisé pour évaluer les changements monocytaires entre normo-glycémie (NG), pré-diabète(PrDt) et DT2. La relation entre leurs lipidomes et les caractéristiques des Mono a été étudiée. Les Mono analysés par IP de patients hospitalisés pour COVID19 sévère, DT2 ou non, ont été comparés. Résultats : Dans la population DT2, le compte de Mono est associé au sexe, au tabagisme, à la créatininémie et au RCV. Seuls les Mono classiques (MC) sont associés au RCV. Le pourcentage de MC augmente entre NG, PrDt et DT2 sans relation identifiée avec les modifications lipidomiques. Les patients DT2/COVID19 avaient une moins de mono (diminution des MC) par rapport aux non-DT2/COVID19, mais des plus gros. Conclusion : De par leurs modifications de répartition, les Mono semblent bien associés à la pathogenèse du DT2 et de ses complications. Néanmoins leurs rôles exacts restent à explorer avant de pouvoir imaginer en faire une cible thérapeutique.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude du rôle des monocytes dans la pathogénèse du diabète et de ses complications
Introduction: Les patients diabétiques de type 2 (DT2) sont à haut risque de complications cardiovasculaires (CV) et de formes graves de COVID19. Le DT2, l’athérosclérose et le COVID-19 ont une pathogenèse liée à un état inflammatoire pathologique. Les monocytes (Mono) sont capables d’avoir une action propre anti- ou pro-inflammatoire, mais aussi de s’infiltrer dans les tissus et de s’y différencier en macrophages. Nous testons l’hypothèse qu’ils pourraient être associés à la mise en place du diabète et de ces 2 complications. Méthodes : Les Mono (totaux et sous-types) d’une cohorte de DT2 ont été quantifiés (en immunophénotypage(IP)), leurs corrélations avec les données clinicobiologiques et CV ont été étudiées. Le modèle du diabète gestationnel a été utilisé pour évaluer les changements monocytaires entre normo-glycémie (NG), pré-diabète(PrDt) et DT2. La relation entre leurs lipidomes et les caractéristiques des Mono a été étudiée. Les Mono analysés par IP de patients hospitalisés pour COVID19 sévère, DT2 ou non, ont été comparés. Résultats : Dans la population DT2, le compte de Mono est associé au sexe, au tabagisme, à la créatininémie et au RCV. Seuls les Mono classiques (MC) sont associés au RCV. Le pourcentage de MC augmente entre NG, PrDt et DT2 sans relation identifiée avec les modifications lipidomiques. Les patients DT2/COVID19 avaient une moins de mono (diminution des MC) par rapport aux non-DT2/COVID19, mais des plus gros. Conclusion : De par leurs modifications de répartition, les Mono semblent bien associés à la pathogenèse du DT2 et de ses complications. Néanmoins leurs rôles exacts restent à explorer avant de pouvoir imaginer en faire une cible thérapeutique.
- Open Access
- 24 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1179-1190
A nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
Aims: A nationwide observational study was conducted to assess the 12‐month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D). Methods: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9–10 mmol/L) after 1 year with AID. Results: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control‐IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant ( p < 0.05). Only 2.8% of PwT1D discontinued AID. Conclusions: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.
- 24 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (2) , 1179-1190
Open AccessA nationwide 12‐month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events
Aims: A nationwide observational study was conducted to assess the 12‐month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D). Methods: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9–10 mmol/L) after 1 year with AID. Results: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control‐IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant ( p < 0.05). Only 2.8% of PwT1D discontinued AID. Conclusions: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.
- Open Access
- 8 October 2025
- Published by Springer Nature in Research Square
Immune Cell-Based Clustering Reveals Clinically Distinct Endotypes in Type 2 Diabetes
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications fail to capture its complexity or enable precision care. Here, we introduce a clinically scalable, immune-based endotyping strategy using routine blood immune cell counts - neutrophils, lymphocytes, and monocytes - from over 1,500 individuals with newly diagnosed T2D across three independent longitudinal European cohorts. Unsupervised clustering identified four consistent and clinically meaningful immune endotypes: Severe Inflammatory Diabetes (SIND), Mild Inflammatory Diabetes (MIND), Lymphocyte-Rich Diabetes (LYRD), and Lymphocyte-Deficient Diabetes (LYDD), that named immunotypes. These endotypes were associated with divergent long-term outcomes, with SIND and LYDD showing increased cardiovascular, renal, and mortality risks, and MIND and LYRD linked to more favorable trajectories. Multi-omic profiling revealed endotype-specific inflammatory signatures, including selective expansion of CCR2hi and CD39hi classical monocytes in the SIND endotype. Integration with single-cell RNA-seq uncovered distinct monocyte subsets in SIND, enriched for chemotaxis and myeloid activation transcriptional programs, alongside skewed adaptive immunity. Strikingly, this pro-inflammatory immune profile was attenuated by IL-1β antagonism and bariatric surgery-induced diabetes remission, underscoring its therapeutic relevance. These findings position immune-based endotyping as a robust and accessible tool to stratify risk, uncover disease mechanisms, and guide personalized intervention strategies in T2D.
- 8 October 2025
- Published by Springer Nature in Research Square
Open AccessImmune Cell-Based Clustering Reveals Clinically Distinct Endotypes in Type 2 Diabetes
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications fail to capture its complexity or enable precision care. Here, we introduce a clinically scalable, immune-based endotyping strategy using routine blood immune cell counts - neutrophils, lymphocytes, and monocytes - from over 1,500 individuals with newly diagnosed T2D across three independent longitudinal European cohorts. Unsupervised clustering identified four consistent and clinically meaningful immune endotypes: Severe Inflammatory Diabetes (SIND), Mild Inflammatory Diabetes (MIND), Lymphocyte-Rich Diabetes (LYRD), and Lymphocyte-Deficient Diabetes (LYDD), that named immunotypes. These endotypes were associated with divergent long-term outcomes, with SIND and LYDD showing increased cardiovascular, renal, and mortality risks, and MIND and LYRD linked to more favorable trajectories. Multi-omic profiling revealed endotype-specific inflammatory signatures, including selective expansion of CCR2hi and CD39hi classical monocytes in the SIND endotype. Integration with single-cell RNA-seq uncovered distinct monocyte subsets in SIND, enriched for chemotaxis and myeloid activation transcriptional programs, alongside skewed adaptive immunity. Strikingly, this pro-inflammatory immune profile was attenuated by IL-1β antagonism and bariatric surgery-induced diabetes remission, underscoring its therapeutic relevance. These findings position immune-based endotyping as a robust and accessible tool to stratify risk, uncover disease mechanisms, and guide personalized intervention strategies in T2D.
- Open Access
- 5 September 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (6) , 101700
Incidence of death and amputation in patients with a first diabetic foot ulcer: results from the CODIA cohort
- 5 September 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (6) , 101700
Open AccessIncidence of death and amputation in patients with a first diabetic foot ulcer: results from the CODIA cohort
- 12 July 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (7) , 442-448
Assessment of the Impact of Subcutaneous Catheter Change on Glucose Control in Patients with Type 1 Diabetes Treated by Insulin Pump in Open- and Closed-Loop Modes
Introduction: Most continuous subcutaneous insulin infusion (CSII) catheters (KT) are changed every 3 days. This study aims at evaluating whether KT changes impact glucose control while under open-loop (OL) or automated insulin delivery (AID) modes. Methods: We included patients with type 1 diabetes who used Tandem t:slim x2 insulin pump and Dexcom G6 glucose sensor for 20 days in OL, then as AID. CSII and sensor glucose data in OL and for the past 20 days of 3-month AID were retrospectively analyzed. The percentage of time spent with sensor glucose above 180 mg/dL (%TAR180) was compared between the calendar day of KT change (D0), the next day (D1), and 2 days later (D2). Values were adjusted for age, gender, body mass index (BMI), hemoglobin A1c (HbA1c) at inclusion, and %TAR180 for the 2 h before KT change. Results: A total of 1636 KT changes were analyzed in 134 patients: 72 women (54%), age: 35.6 ± 15.7 years, BMI: 25.2 ± 4.7 kg/m 2 , and HbA1c: 7.5 ± 0.8%. %TAR180 in the 2 h before the KT change was 51.3 ± 37.0% in OL and 33.2 ± 30.0% in AID mode. In OL, significant absolute increases of %TAR180 at D0 versus D1 (+6.9%; P < 0.0001) or versus D2 (+6.8%; P < 0.0001) were observed. In AID, significant absolute increases of %TA180R at D0 versus D1 (+4.8%; P < 0.0001) or versus D2 (+4.2%; P < 0.0001) were also observed. Conclusion: This study shows an increase in time spent in hyperglycemia on the day of the KT change both in OL and AID modes. This additional information should be taken into account to improve current AID algorithms. ClinicalTrials.gov: NCT 04939766.
- 12 July 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (7) , 442-448
Assessment of the Impact of Subcutaneous Catheter Change on Glucose Control in Patients with Type 1 Diabetes Treated by Insulin Pump in Open- and Closed-Loop Modes
Introduction: Most continuous subcutaneous insulin infusion (CSII) catheters (KT) are changed every 3 days. This study aims at evaluating whether KT changes impact glucose control while under open-loop (OL) or automated insulin delivery (AID) modes. Methods: We included patients with type 1 diabetes who used Tandem t:slim x2 insulin pump and Dexcom G6 glucose sensor for 20 days in OL, then as AID. CSII and sensor glucose data in OL and for the past 20 days of 3-month AID were retrospectively analyzed. The percentage of time spent with sensor glucose above 180 mg/dL (%TAR180) was compared between the calendar day of KT change (D0), the next day (D1), and 2 days later (D2). Values were adjusted for age, gender, body mass index (BMI), hemoglobin A1c (HbA1c) at inclusion, and %TAR180 for the 2 h before KT change. Results: A total of 1636 KT changes were analyzed in 134 patients: 72 women (54%), age: 35.6 ± 15.7 years, BMI: 25.2 ± 4.7 kg/m 2 , and HbA1c: 7.5 ± 0.8%. %TAR180 in the 2 h before the KT change was 51.3 ± 37.0% in OL and 33.2 ± 30.0% in AID mode. In OL, significant absolute increases of %TAR180 at D0 versus D1 (+6.9%; P < 0.0001) or versus D2 (+6.8%; P < 0.0001) were observed. In AID, significant absolute increases of %TA180R at D0 versus D1 (+4.8%; P < 0.0001) or versus D2 (+4.2%; P < 0.0001) were also observed. Conclusion: This study shows an increase in time spent in hyperglycemia on the day of the KT change both in OL and AID modes. This additional information should be taken into account to improve current AID algorithms. ClinicalTrials.gov: NCT 04939766.
- 19 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (2) , 189-202
Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes
BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis. METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D. RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype. CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04353869
- 19 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (2) , 189-202
Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes
BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis. METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D. RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype. CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04353869
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 631
Étude de l’influence du contrôle glycémique sur les capacités cognitives chez les patients DT1 adultes
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 631
Étude de l’influence du contrôle glycémique sur les capacités cognitives chez les patients DT1 adultes
- Open Access
- 27 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12053
Untargeted Multiomics Approach Coupling Lipidomics and Metabolomics Profiling Reveals New Insights in Diabetic Retinopathy
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus (DM) which is the main cause of vision loss in the working-age population. Currently known risk factors such as age, disease duration, and hemoglobin A1c lack sufficient efficiency to distinguish patients with early stages of DR. A total of 194 plasma samples were collected from patients with type 2 DM and DR (moderate to proliferative (PDR) or control (no or mild DR) matched for age, gender, diabetes duration, HbA1c, and hypertension. Untargeted lipidomic and metabolomic approaches were performed. Partial-least square methods were used to analyze the datasets. Levels of 69 metabolites and 85 lipid species were found to be significantly different in the plasma of DR patients versus controls. Metabolite set enrichment analysis indicated that pathways such as metabolism of branched-chain amino acids (methylglutaryl carnitine p = 0.004), the kynurenine pathway (tryptophan p < 0.001), and microbiota metabolism (p-Cresol sulfate p = 0.004) were among the most enriched deregulated pathways in the DR group. Moreover, Glucose-6-phosphate (p = 0.001) and N-methyl-glutamate (p < 0.001) were upregulated in DR. Subgroup analyses identified a specific signature associated with PDR, macular oedema, and DR associated with chronic kidney disease. Phosphatidylcholines (PCs) were dysregulated, with an increase of alkyl-PCs (PC O-42:5 p < 0.001) in DR, while non-ether PCs (PC 14:0–16:1, p < 0.001; PC 18:2–14:0, p < 0.001) were decreased in the DR group. Through an unbiased multiomics approach, we identified metabolites and lipid species that interestingly discriminate patients with or without DR. These features could be a research basis to identify new potential plasma biomarkers to promote 3P medicine.
- 27 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12053
Open AccessUntargeted Multiomics Approach Coupling Lipidomics and Metabolomics Profiling Reveals New Insights in Diabetic Retinopathy
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus (DM) which is the main cause of vision loss in the working-age population. Currently known risk factors such as age, disease duration, and hemoglobin A1c lack sufficient efficiency to distinguish patients with early stages of DR. A total of 194 plasma samples were collected from patients with type 2 DM and DR (moderate to proliferative (PDR) or control (no or mild DR) matched for age, gender, diabetes duration, HbA1c, and hypertension. Untargeted lipidomic and metabolomic approaches were performed. Partial-least square methods were used to analyze the datasets. Levels of 69 metabolites and 85 lipid species were found to be significantly different in the plasma of DR patients versus controls. Metabolite set enrichment analysis indicated that pathways such as metabolism of branched-chain amino acids (methylglutaryl carnitine p = 0.004), the kynurenine pathway (tryptophan p < 0.001), and microbiota metabolism (p-Cresol sulfate p = 0.004) were among the most enriched deregulated pathways in the DR group. Moreover, Glucose-6-phosphate (p = 0.001) and N-methyl-glutamate (p < 0.001) were upregulated in DR. Subgroup analyses identified a specific signature associated with PDR, macular oedema, and DR associated with chronic kidney disease. Phosphatidylcholines (PCs) were dysregulated, with an increase of alkyl-PCs (PC O-42:5 p < 0.001) in DR, while non-ether PCs (PC 14:0–16:1, p < 0.001; PC 18:2–14:0, p < 0.001) were decreased in the DR group. Through an unbiased multiomics approach, we identified metabolites and lipid species that interestingly discriminate patients with or without DR. These features could be a research basis to identify new potential plasma biomarkers to promote 3P medicine.